Impact of the hemoadsorption with Cytosorb on hemodynamic in pediatric patients with septic shock: a prospectic pediatric pilot study
Prospective interventional pilot study included children with septic shock, weight ≥ 10 Kgs and requiring continuous kidney replacement therapy. Cytosorb (CytoSorbents Inc, New Jersey, USA) cartridge was added to CKRT every 24 hours for a maximum of 96 hours. A control group of matched patients was also identified from an external database. The primary outcome of the study was the proportion of patients who achieved an equal or more than 50% relative reduction in vasopressors or inotropes dose from baseline to the end of treatment. Secondary outcomes included doses of vasopressors and inotropes, hemodynamic and biological changes, changes in severity scores and 28-day mortality.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
17
Cytosorb cartridge It is composed of polystyrene divinylbenzene and polyvinylpyrrolidone copolymers and targets molecules in the 5-50 kDa range, which includes the molecular mass of several cytokines
Gabriella Bottari
Rome, Italy
Vasopressors and inotropes reduction
Proportion of patients who achieved a significant reduction in vasopressors or inotropes dose from baseline to the end of treatment.
Time frame: 96 hours
Changes in hemodynamic parameters
changes in CI, SVRI, systolic pressure - Psys, diastolic pressure - Pdia, and mean pressure
Time frame: 96 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.